#### SMITH & NEPHEW PLC

#### 21 May 2025

## NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

#### 1. VESTING OF SHARE AWARDS UNDER THE GLOBAL SHARE PLAN 2020

On 20 May 2025, the Company received notification of the following transactions in US 0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") following the vesting of awards under the Smith & Nephew Global Share Plan 2020.

All figures in these columns are stated to 6 decimal places where applicable.

# i. VESTING OF PERFORMANCE SHARE PLAN AWARDS MADE UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020

The awards were granted under the Global Share Plan 2020 and vested on 20 May 2025 at 59.35% of target. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards as detailed in the table below. The number of Shares acquired includes the dividend equivalent Shares which the participant received on the vested Shares. The table below sets out the number of shares under award which vested. The remaining shares under award have lapsed.

Reason for the notification						
Initial notification /Amendment	Initial notification					
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
Name	Smith & Nephew plc					
LEI	213800ZTMDN8S67S1H61					
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
Description of the financial instrument, type of instrument	Smith & Nephew plc ordinary shares of USD 0.20 each					
Identification code	ISIN: GB0009223206					
Nature of the transaction	Vesting on 20 May 2025 of Performance Share Plan awards granted under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability					
Date of Transaction	2025 - 05 - 20					
Place of Transaction	London Stock Exchange (XLON)					

Name (Position)	Status	Price (£)	Volume	Aggregated information
Deepak Nath (Chief Executive Officer)	PDMR	10.875359	83,938 (of which 34,477 were sold and 49,461 were retained)	N/A Single Transaction

### ii. VESTING OF CONDITIONAL AWARDS MADE UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020

The awards were granted under the Global Share Plan 2020 and vested on 20 May 2025. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards as detailed in the table below.

The following relates to individuals included in the below notification:

Reason for the notification						
Initial notification /Amendment Initial notification						
Initial Hotification / Amenument						
Details of the issuer, emission allowance market participant, auction platform, auctioneer						
or auction monitor						
Name	Smith & Nephew plc					
LEI	213800ZTMDN8S67S1H61					
Details of the transaction(s): se	ction to be repeated for (i) each type of instrument; (ii) each					
type of transaction; (iii) each date; and (iv) each place where transactions have been						
conducted						
Description of the financial	Smith & Nephew plc ordinary shares of USD 0.20 each					
instrument, type of instrument						
Identification code	ISIN: GB0009223206					
Nature of the transaction	Vesting on 20 May 2025 of Conditional Share awards granted					
	under the Smith & Nephew Global Share Plan 2020, and					
	subsequent sale of shares to cover tax liability					
Date of Transaction	2025 - 05 - 20					
Place of Transaction	London Stock Exchange (XLON)					

Name (Position)	Status	Price (£)	Volume	Aggregated information
Craig Gaffin (President, Global Orthopaedics)	PDMR	10.875359	1,551 (of which 379 were sold and 1,172 were retained)	N/A Single Transaction
Elga Lohler (Chief HR Officer)	PDMR	10.875359	20,174 (of which 8,026 were sold and 12,148 were retained)	N/A Single Transaction
Vasant Padmanabhan (President Research & Development and ENT)	PDMR	10.875359	19,626 (of which 8,708 were sold and 10,918 were retained)	N/A Single Transaction
Rohit Kashyap (President, Advanced Wound Management and Global Commercial Operations)	PDMR	10.875359	11,949 (of which 2,920 were sold and 9,029 retained)	NA Single Transaction

Philip Homer Deputy Company Secretary Smith & Nephew plc

Tel: +44 (0)1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END